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1. Introduction
Since the discovery of nerve growth factor (NGF) about 60 
years ago, extensive studies have elaborated on the trophic 
relationship between a neuron and its end organ. Substantial 
evidence has accumulated that depicts the crucial role of 
neurotrophic factors in determining neuronal survival, 
both during development and after injury. NGF is known 
as a molecule that promotes the survival and differentiation 
of sensory and sympathetic neurons (1–3). Its roles in 
neural development have been characterized extensively, 
but recent findings point to a diversity of NGF actions 
and indicate that developmental effects are not the only 
aspect of the biology of NGF. It is thought that NGF roles 
begin in development and extend throughout adult life and 
aging, involving a surprising variety of neurons, glia, and 
nonneural cells. NGF also influences the reaction of the 
neuron to axotomy and subsequent axonal regeneration 
(4,5). Particular attention is now being given to a growing 
body of evidence that suggests that, among other roles, 
endogenous NGF signaling provides neuroprotective 
and repair functions (6,7). Exogenously supplied NGF 
was demonstrated to prevent neuronal loss after axotomy 
when supplied at the site of injury (8). Furthermore, it 
was reported that reduction in NGF availability leads to 
a conditioning lesion-like effect on sympathetic neurons. 
Results of that study suggested that this effect might be 
due to the decreased ability of sympathetic neurons to 
accumulate NGF after axotomy (9). Considerable studies 
support the evidence regarding the localization of NGF 
within the central nervous system (CNS) and its presumed 
role in maintaining basal forebrain cholinergic neurons, 
given the original suggestion that certain human neurologic 
disorders may be caused by reductions in NGF in certain 
brain regions in Alzheimer disease (10). It was suggested 
that NGF may be useful in slowing the progression of 
Alzheimer-related cholinergic basal forebrain atrophy, 
perhaps by easing the cognitive deficit associated with the 
disorder (10,11).
At present, the Alzheimer’s Association uses a checklist 
of 10 warning signs for the disease: “1 - memory loss, 
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2 - difficulty performing familiar tasks, 3 - problems 
with language, 4 - disorientation to time and place, 5 - 
poor or decreased judgment, 6 - problems with abstract 
thinking, 7 - misplacing things, 8 - changes in mood or 
behavior, 9 - changes in personality, 10 - loss of initiative” 
(http://www.alz.org/alzheimers_disease_10_signs_of_
alzheimers.asp). In addition, it is suggested that the use 
of the Patient Behavior Triggers for Clinical Staff and 
family questionnaires would identify many individuals 
with possible dementia. These measures, however, lack 
pathological specificity, as some of the criteria might be 
applicable to other dementing illnesses. In order to deal 
with this difficulty, several studies have focused on the 
detection of neuronal components in biological fluids as 
biomarkers of the brain. These studies are based on the 
concept that the release of these components into the 
surrounding extracellular gap might be detectable in bodily 
fluids. The specific biological functions of NGF actions 
are modulated via the specific NGF receptors (NGFRs) 
of the target cells. It has been shown that the common 
NGFR (p 75 neurotrophin receptor, p75NTR) is highly 
expressed in the CNS during embryonic development 
and downregulated to a detectable trace level during the 
postmaturation phase, but pathological factors stimulate 
NGFR synthesis and release the extracellular parts of 
the receptors as the truncated soluble form (TNGFR) to 
biological fluids (12–15). The objective of this pilot study 
was to use an indirect quenching fluoroimmunoassay to 
determine urine TNGFR levels in patients with dementia 
and to verify whether TNGFR has the potential of being a 
marker of Alzheimer disease progression.
2. Materials and methods 
2.1. Chemicals
Nerve growth factor (purified 75 NGF), fluorescein 
isothiocyanate isomer 1 (FITC), Freund’s adjuvant 
(complete and incomplete), Sephadex G-25, and agarose 
were purchased from Sigma (Poole, UK). Unless stated 
otherwise, all reagents were of the highest grade and made 
up in double glass-distilled water.
2.2. Patients and samples 
Twelve patients with dementia were asked to participate 
in this study voluntarily. The clinical presentation and 
diagnostic investigations were confirmed by a clinical 
specialist. The patients were divided into 3 age groups 
according their ages: group 1 (52–63 years), group 2 
(63–77 years), and group 3 (77–87 years). Twelve healthy 
volunteers with no apparent signs of dementia were 
included as a control population. Adjustments for age, 
sex, and weight were made in the selection of the control 
group. The first morning urine samples were collected and 
urine TNGFR was assayed the same day.
2.3. Fluorescein-labeled NGF 
Fluorescein-labeled NGF was prepared as described by 
Messripour and Moein (16). Equal volumes of FITC 
solution (1 mg/mL) and purified NGF solution (about 0.25 
mg protein/mL) were mixed and stirred overnight at 4 °C. 
The labeled NGF was separated from unconjugated FITC 
using Sephadex G-25 columns (1.2 × 20 cm).
2.4. Antifluorescein antibody
Four male albino rabbits (1.5–1.7 kg) were immunized 
with fluorescein-labeled NGF as recommended by London 
and Moffat (17). For determination of antifluorescein 
antibody, a double-dilution serum was made in Tris-HCl 
buffer (pH 7.4); 100 µL of fluorescein-labeled NGF solution 
(2.5 µg protein) was added to 100 µL of each dilution and 
mixed. After 15 min of incubation at room temperature, 
the volume was increased up to 2 mL by addition of the 
buffer. The fluorescence intensities of the mixture were 
measured using a PerkinElmer (Norwalk, CT, USA) LSE 
spectrophotofluorometer with excitation wavelength of 
495 nm and emission wavelength of 540 nm fluorescence, 
and antifluorescein titer was measured by the ability to 
quench fluorescein-labeled NGF.
2.5. Determination of TNGFR
The concentrations of TNGFR were measured by indirect 
quenching fluoroimmunoassay essentially as described by 
Messripour and Moein (16). Briefly, fluorescein-labeled 
NGF (100 µL) was added to triplicate tubes containing 
100 µL of urine samples. After 5 min, 100 µL of a 1:100 
diluted antifluorescein serum (rabbit) in saline was added, 
and after 15 min of incubation at room temperature, the 
volume was increased up to 2 mL by addition of Tris 
buffer and fluorescence intensities of the mixture were 
measured spectrofluorometrically as described above. In 
all experiments, a correction was made for the background 
signal contributed by reactions other than that of the 
fluorescein-labeled NGF. The amount of TNGFR is 
expressed as ng/mL of fluorescein-labeled NGF that 
remained fluorescent. All samples were run in duplicate, 
and the average value is reported.
2.6. Gel diffusion method
Agarose gel diffusion of NGF against urine samples was 
carried out as described by Ouchterlong (18). Agarose 
(1%) in buffer containing NGF was layered on a plastic 
plate. The urine samples taken from diagnosed patients 
and apparently normal subjects were pipetted into the gel 
wells. The plates were placed in the cold room for 72 h and 
a radial band around the wells was considered as positive.
2.7. Statistical analysis
The obtained data were subjected to statistical analysis 
using SPSS 18. In all cases, one-way analysis of variance 
(ANOVA) was used to compare the mean of each group 
with that of the control group. The least significant 
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difference complementary test was conducted to determine 
exact differences at P-values of lower than 0.05. Data are 
presented as mean ± SD for all cases.
3. Results
The quality of the antibody and its application for the 
assay was evaluated and is summarized in Table 1. 
Addition of the antifluorescein serum (1:100 dilution) 
with or without healthy urine samples caused a marked 
decrease in fluorescence of the fluorescein-labeled NGF 
from 89 to 26 units, whereas the additions of 100 µL of 
rabbit control serum (1:100 dilution) or healthy urine 
sample (100 µL) in the buffer (final volume: 2 mL) did not 
change the fluorescence intensity significantly. Conversely, 
the addition of a patient’s urine (100 µL) to the mixture 
of the fluorescein-labeled NGF and antifluorescein 
serum resulted in the enhancement of the fluorescence 
intensity to about the unit value of the fluorescein-
labeled NGF in the buffer. These results indicate that the 
binding of fluorescein residues by antifluorescein serum 
caused efficient quenching of fluorescence, whereas the 
enhancement of the fluorescence intensity in the presence 
of TNGFR is best explained in terms of inhibition of 
quenching of the labeled NGF (Figure 1). It appears that 
when the NGF moiety becomes interlocked with the 
combining site of the TNGFR, because of strict hindrance 
selectivity, antifluorescein antibody cannot quench the 
fluorescence intensity of the labeled NGF (Figure 1). This 
is in good agreement with reports of other investigators 
(16).
This method was used to determine TNGFR in the 
urine of patients with dementia (Table 2). The mean 
level of TNGFR in the urine samples of healthy control 
subjects and the patients with dementia was 164 ± 23 and 
341 ± 66 ng/mg creatinine, respectively. The value for the 
patients was about 2-fold greater than that recorded for the 
healthy control subjects. The differences were statistically 
significant (P < 0.05). Table 2 shows comparative studies 
of urinary TNGFR as assayed by both fluoroimmunoassay 
and agarose gel diffusion in different subgroups of both 
patients and healthy subjects (Figure 2). As can be seen in 
Table 2, there is a relationship between the levels of NGFR 
in different ages of both control and patient subgroups.
4. Discussion
The results obtained in this work showed that the abnormal 
levels of TNGFR are higher in the urine of patients with 
dementia as compared to that of healthy subjects. This 
supports the results of Lindner et al. (19), who reported 
that urine TNGFR levels were elevated in mildly demented 
patients relative to nondemented controls. NGF and its 
low-affinity receptor are abundantly present within the 
dementing brain, although this does not rule out an NGF-
related mechanism in the degeneration of basal forebrain 
neurons, nor does it eliminate the possibility that exogenous 
NGF may be successfully used to treat Alzheimer disease 
(10,11). TNGFR has been found in newborn infant 
urine, but declines to low detectable levels in adult urine 
(12). Importantly, TNGFR was found in urine of rats 
following sciatic nerve injury, but it is hardly detectable 
in normal adult rat urine (12). These studies suggest that 
the extracellular fragment of the receptor is detached 
after injury and excreted in the urine. The higher levels 
of TNGFR observed in the patients may be interpreted as 
being consistent with the upregulation of NGF receptors 
in the brains of demented patients to represent an adaptive 
Table 1. Quenching effect of TNGFR on the mixture of fluorescein-labeled 
NGF and antifluorescein antibody,.
Reagents Fluorescence intensities
Buffer 00 ± 0
Buffer + fNGF 89 ± 3
Buffer + fNGF + rabbit control serum 83 ± 4
Buffer + fNGF + rabbit antifluorescein 26 ± 2
Buffer + fNGF + patient urine sample 91 ± 5
Buffer + fNGF + healthy urine sample 89 ± 5
Buffer + fNGF + antifluorescein + control urine 29 ± 2
Buffer + fNGF + antifluorescein + patient urine 87 ± 3
Fluorescein-labeled NGF (fNGF) was incubated with the indicated reagent 
(100 µL) in a total volume of 2 mL and fluorescence intensities (arbitrary units) 
were measured as described in Section 2. The results are means and standard 
deviations of 20 separate determinations.
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response to the reduction of NGF (14). However, further 
studies of the degree and distribution of NGF within the 
human brain in normal aging and in Alzheimer disease, 
and of the possible relationship between target NGF levels 
and the status of basal forebrain neurons in vivo, are 
necessary before engaging in clinical trials.
Biomarkers that reflect the progression of dementia 
will improve the survey of clinical assessments and 
permit for more rapid screening of the population with 
smaller numbers of patients for identifying demented 
patients earlier and improving the effectiveness of 
treatment. Clinical utility of objective biomarkers may 
require a combination of physiological and biochemical 
methodologies. The immunological reaction and the high 
degree of fluorescence sensitivity indicate that indirect 
quenching fluoroimmunoassay is accurate and sensitive 
enough for the screening of a large number of urin 
samples for the measurement of TNGFR for identification 
of people who are at risk of Alzheimer disease.
It is concluded that the present method for urine 
samples may provide a suitable measure of dementia-
related neuropathological changes, but further study is 
needed to determine the source and potential clinical 
utility of increased TNGFR levels in the urine of demented 
patients.
Table 2. Comparison of TNGFR levels in urine of patients with dementia and 
healthy individuals.
Samples Age (years) ng TNGFR/mg creatinine Gel diffusion
Patients
Group 1 52–63 276 ± 47 [4] UN [3], + [1]
Group 2 64–77 353 ± 71 [4] + [2], ++ [2]
Group 3 78–87 388 ± 64 [4] +++ [4]
Controls
Group 1 52–63 106 ± 18 [4] UD [4]
Group 2 64–77 173 ± 12 [4] UD [3], WP [1]
Group 3 78–87 202 ± 37 [4] UD [3], + [1]
NGFR was assayed either by fluoroimmunoassay or agarose gel diffusion in 
urine samples from patients with dementia and healthy individuals. Ages were 
matched and are shown as different subgroups. Numbers in each subgroup are 
given in brackets. SD = Standard deviation, UD = undetectable.
Figure 1. The competitive selectivity of antifluorescein (anti-F) 
and TNGFR for binding to fluorescein-labeled NGF (F-NGF). 
The amount of TNGFR is expressed as ng/mL of F-NGF that 
remained fluorescent.
Figure 2. Agarose gel diffusion of urine samples against 
fluorescein-labeled NGF. Agarose in buffer containing NGF was 
layered on a plastic plate and urine samples taken from patients 
and control subjects were pipetted into the gel wells. The radial 
band around the wells was considered as positive.
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